A Phase 2 Study of a Subcutaneous Injection of TAK-850 in Healthy Adult Participants

Influenza Prevention Clinical Trial

Official title:
An Open-label Phase 2 Study to Evaluate the Safety and Immnogenicity of a Single Subcutaneous Injection of Quadrivalent TAK-850 in Healthy Adult Subjects

Status Withdrawn

Clinical Trial Summary

This clinical trial is a Phase 2 study of a single subcutaneous injection of TAK-850 for 22 days in healthy Japanese adults.

Clinical Trial Description

The primary objective of this study is to evaluate the safety and immunogenicity of a single subcutaneous injection of TAK-850 for 22 days in healthy Japanese adults. ;

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Influenza Prevention

Clinical Trial Details

NCT number	NCT02713061
Study type	Interventional
Source	Takeda
Contact
Status	Withdrawn
Phase	Phase 2
Start date	March 2016
Completion date	April 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06280144` - Post-marketing Study of Lyophilized Nasal Spray Live Attenuated Influenza Vaccine	Phase 4
Recruiting	`NCT05056519` - The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine	Phase 1
Active, not recruiting	`NCT05901636` - A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults	Phase 1/Phase 2
Not yet recruiting	`NCT05284851` - The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine	Phase 2